Review of the fibrinolytic system: Comparison of different antifibrinolytics used during cardiopulmonary bypass

Recent Patents on Cardiovascular Drug Discovery

Volumn 7, Issue 3, 2012, Pages 175-179

  van Aelbrouck, Caroline ^a   Englberger, Lars ^b   Faraoni, David ^c  

^a ERASME HOSPITAL   (Belgium)

^b UNIVERSITY OF BERN   (Switzerland)

^c HOP UNIV DES ENFANTS REINE FABIOLA   (Belgium)

Author keywords

Antifibrinolytics; Aprotinin; Epsilon aminocaproic acid; Fibrinolysis; Tranexamic acid

Indexed keywords

AMINOCAPROIC ACID; AMINOCAPROIC ACID EPSILON; ANTIFIBRINOLYTIC AGENT; APROTININ; KALLIKREIN; PLACEBO; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

CARDIOPULMONARY BYPASS; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYSIS; HEART SURGERY; HUMAN; PRIORITY JOURNAL; REVIEW;

ANTIFIBRINOLYTIC AGENTS; CARDIOPULMONARY BYPASS; FIBRINOLYSIS; HUMANS; INFLAMMATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT;

EID: 84870215086     PISSN: 15748901     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489012803832793     Document Type: Review

References (48)

1. Koch C. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 2006; 34:1608-16.
2. Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, Blackstone EH. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358:1229-39.
3. Mehta RH, Sheng S, O'Brien SM, Grover FL, Gammie JS, Ferguson TB, et al. Reoperation for bleeding in patients undergoing coronary artery bypass surgery: Incidence, risk factors, time trends, and outcomes. Circ Cardiovasc Qual Outcomes 2009; 2: 583-90.
4. Tagarakis GI, Karangelis D, Daskalopoulos ME, Tsilimingas NB. Dabigatran: The anticoagulant we have long expected? Recent Pat Cardiovasc Drug Discov 2010; 5: 223-26.
5. Van Ryn, J., Park, J., Hauel, N., Kunz, U., Litzenburger, T., Canada, K., Singh, S., Waterman, A. Anticoagulant antidotes. US20120027780A1 (2012).
6. Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et al. The inflammatory response to cardiopulmonary bypass: Part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009; 23: 223-31.
7. Nuttall GA, Oliver WC, Ereth MH, Santrach PJ, Bryant SC, Orszulak TA, et al. Comparison of blood-conservation strategies in cardiac surgery patients at high risk for bleeding. Anesthesiology 2000; 92:674-682.
8. Koster A, Schirmer U. Re-evaluation of the role of antifibrinolytic therapy with lysine analogs during cardiac surgery in the post aprotinin era. Curr Opin Anaesthesiol 2011; 24: 92-97.
9. Aoki N, Sakata Y, Ichinose A. Fibrin-associated plasminogen activation in alpha 2-plasmin inhibitor deficiency. Blood 1983; 62:1118-22.
10. Skultetyova D, Filipova S, Riecansky I, Skultety J. The role of angiotensin type 1 receptor in inflammation and endothelial dysfunction. Recent Pat Cardiovasc Drug Discov 2007; 2: 23-27.
11. Mojcik C. Aprotinin and the Systemic Inflammatory Response After Cardiopulmonary Bypass. Ann Thorac Surg 2001;71:745-54.
12. Weber CF, Gorlinger K, Byhahn C, Moritz A, Hanke AA, Zacharowski K, et al. Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol 2011;28:57-62.
13. Boyle EM, Jr., Pohlman TH, Johnson MC, Verrier ED. Endothelial cell injury in cardiovascular surgery: the systemic inflammatory response. Ann Thorac Surg 1997;63:277-84.
14. Murkin JM. Cardiopulmonary bypass and the inflammatory response: A role for serine protease inhibitors? J Cardiothorac Vasc Anesth 1997;11:19-23
15. Jimenez JJ, Iribarren JL, Lorente L, Rodriguez JM, Hernandez D, Nassar I, et al. Tranexamic acid attenuates inflammatory response in cardiopulmonary bypass surgery through blockade of fibrinolysis: A case control study followed by a randomized double-blind controlled trial. Crit Care 2007;11:R117.
16. Greilich PE, Brouse CF, Whitten CW, Chi L, Dimaio JM, Jessen ME. Antifibrinolytic therapy during cardiopulmonary bypass reduces proinflammatory cytokine levels: A randomized, double-blind, placebo-controlled study of epsilon-aminocaproic acid and aprotinin. J Thorac Cardiovasc Surg 2003;126:1498-1503.
17. Fuhrer G, Gallimore MJ, Heller W, Hoffmeister HE. Aprotinin in cardiopulmonary bypass--effects on the Hageman factor (FXII)--Kallikrein system and blood loss. Blood Coagul Fibrinolysis 1992; 3: 99-104.
18. Brown JR, Birkmeyer NJ, O'Connor GT. Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 2007;115:2801-2813.
19. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM, et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358: 2319-31.
20. Beattie WS, Karkouti K. The Post-BART Anti-Fibrinolytic Dilemma? J Cardiothorac Vasc Anesth 2011; 25:3-5.
21. Faraoni D. Can we really believe that aprotinin is safe in congenital heart surgery? Ann Thorac Surg 2011; 9: 987-8.
22. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994; 80:1013-8.
23. Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, et al. Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: A non-sponsored, double-blind, randomised, placebo-controlled trial. Eur J Cardiothorac Surg 2009; 36: 322-9.
24. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS. The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 2010; 110: 21-29.
25. Senay S, Toraman F, Karabulut H, Alhan C. Efficiency of preoperative tranexamic Acid in coronary bypass surgery: an analysis correlated with preoperative clopidogrel use. Heart Surg Forum 2010;13: E149-154.
26. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C. Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 2010;14:R148.
27. Greilich PE, Jessen ME, Satyanarayana N, Whitten CW, Nuttall GA, Beckham JM, et al. The effect of epsilon-aminocaproic acid and aprotinin on fibrinolysis and blood loss in patients undergoing primary, isolated coronary artery bypass surgery: A randomized, double-blind, placebo-controlled, noninferiority trial. Anesth Analg 2009; 109: 15-24.
28. Ngaage DL, Bland JM. Lessons from aprotinin: Is the routine use and inconsistent dosing of tranexamic acid prudent? Meta-analysis of randomised and large matched observational studies. Eur J Cardiothorac Surg 2010; 37: 1375-83.
29. Mangano DT, Tudor IC, Dietzel C. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006; 354: 353-65.
30. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA, et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Systemat Rev 2011: CD001886.
31. Martin K, Knorr J, Breuer T, Gertler R, Macguill M, Lange R, et al. Seizures after open heart surgery: Comparison of epsilon-aminocaproic acid and tranexamic acid. J Cardiothorac Vasc Anesth 2011; 25: 20-25.
32. Ray WA, Stein CM. The aprotinin story--is BART the final chapter? N Engl J Med 2008; 358: 2398-400.
33. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, et al. The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 2008; 358:784-93.
34. Keyl C, Uhl R, Beyersdorf F, Stampf S, Lehane C, Wiesenack C, et al. High-dose tranexamic acid is related to increased risk of generalized seizures after aortic valve replacement. Eur J Cardiothorac Surg 2011;39: e114-121.
35. Martin K, Wiesner G, Breuer T, Lange R, Tassani P. The risks of aprotinin and tranexamic acid in cardiac surgery: A one-year follow-up of 1188 consecutive patients. Anesth Analg 2008;107: 1783-90.
36. Murkin JM, Falter F, Granton J, Young B, Burt C, Chu M. High-dose tranexamic acid is associated with nonischemic clinical seizures in cardiac surgical patients. Anesth Analg 2010;110: 350-3.
37. Montes FR, Pardo DF, Carreno M, Arciniegas C, Dennis RJ, Umana JP. Risk factors associated with postoperative seizures in patients undergoing cardiac surgery who received tranexamic acid: A case-control study. Ann Cardiac Anaesth 2012; 15: 6-12.
38. Kalavrouziotis D, Voisine P, Mohammadi S, Dionne S, Dagenais F. High-dose tranexamic acid is an independent predictor of early seizure after cardiopulmonary bypass. Ann Thorac Surg 2012; 93:148-154.
39. Lopategui, J., Rodriguez, G.J., Paramo, F.J., Derrano, V.R. Compositions for anti-fibrinolytic treatment. US201001235986A1 (2010).
40. Virsik, P., Canafax, D. Uses of acyloxyalkyl carbamate prodrugs of tranexamic acid. US20110060040A1 (2011).
41. Ladner R, Ley A, Hirani S, Williams A. Prevention and reduction of blood loss. US 8124586B2 (2012).
42. Blair, H., Beck, T., Ladner, R. Kallikrein inhibitors and anti-thrombotic agents and uses thereof. US8188045B2 (2012).
43. Sinha, S., Chilcote, T. Inhibitors of plasma kallikrein. US20080038276 A1 (2008).
44. Bokesch PM, Szabo G, Wojdyga R, Grocott HP, Smith PK, David Mazer C, et al. A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). J Thorac Cardiovac Surg 2012; 143:1022-9.
45. Dietrich W, Nicklisch S, Koster A, Spannagl M, Giersiefen H, van de Locht A. CU-2010--a novel small molecule protease inhibitor with antifibrinolytic and anticoagulant properties. Anesthesiology 2009; 110:123-30.
46. Szabo G, Veres G, Radovits T, Haider H, Krieger N, Bahrle S, et al. Effects of novel synthetic serine protease inhibitors on postoperative blood loss, coagulation parameters, and vascular relaxation after cardiac surgery. J Thorac Cardiovac Surg 2010;139:181-8.
47. Englberger L, Eberle B, Dietrich W, van de Locht A, Carrel T. First-In-Patient experience with the novel synthetic serine protease inhibitor MDCO-2010 in primary CABG surgery. American Society of Anesthesiology (ASA). Chicago, IL, US, 2011.
48. th Annual Meeting. Fort Lauderdale, Florida, US, 2012.